Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results.  Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business.  Unless otherwise noted, Amgen is providing this information as of Oct. 4, 2013, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project.  Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product.  Further, preclinical results do not guarantee safe and effective performance of product candidates in humans.  The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models.  The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... advanced cell culture products, announces the availability of BI’s line of human mesenchymal ... Industries, these stem cell differentiation media offer a complete system for multipotency evaluation ...
(Date:7/29/2015)... ... July 29, 2015 , ... Nearly everyone has heard ... Yet few people realize that a rich source of these cells is teeth—baby teeth ... teeth that need to be pulled to make room for braces. These potent ...
(Date:7/28/2015)... ... 29, 2015 , ... Strong Animals™ announced today that research conducted by South ... at the ADSA-ASAS Joint Annual Meeting held July 12-16 in Orlando, FL showed feed ... milk fat content. Also, feed containing Stay Strong™ for Dairy Cows took longer than ...
(Date:7/28/2015)... 2015  PDL BioPharma, Inc. (PDL, or the Company) ... will release its second quarter 2015 financial results for ... 5, 2015, after market close. PDL,s management will host ... p.m. Eastern Time to discuss the financial results.  A ... via the webcast link on the PDL website. ...
Breaking Biology Technology:Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... J. Beck and C. Schmidt , ... Introduction , Ritanserin (Tisterton) ... anxiety and depression 1 while Raclopride acts as a dopamine D2 receptor ... the Varian 1200L LC/MS/MS in selected reaction monitoring mode (SRM). Studies have shown ...
... , Z. Yang and S. ... Introduction , Amphetamine ... place, and by recreational users. Forensic, clinical, and doping laboratories are ... Urine samples are most common because large sample volumes can be ...
... D Garteiz, TexMS Analytical Services, Houston, TX , ... A Varian 1200L LC/MS/MS system was used for the quantitation of ... the urinary tract using a urethra suppository mode of administration. , ... a major health problem in the U.S. and will continue to grow ...
Cached Biology Technology:Femtogram Sensitivity of the Antipsychotic Drugs Raclopride and Ritanserin Using a Varian 1200L LC/MS/MS 2Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS 2Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS 3Quantitation of Oxybutynin in Rabbit Plasma Using the Varian 1200L LC/MS/MS System 2Quantitation of Oxybutynin in Rabbit Plasma Using the Varian 1200L LC/MS/MS System 3
(Date:7/2/2015)... , June 25, 2015 ... announced the addition of the "Natural Language ... Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... their offering. The key vendors occupying ... HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS ...
(Date:6/29/2015)... DUBLIN , June 24, 2015 ... the addition of the "Latin America Biomedical Sensors ... to their offering. The Latin America Biomedical ... at a CAGR of 2.04% over the period 2014-2020 ... that are adaptable to the genetic formulation of each ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... System scientists from the departments of nutrition and food ... for the cultivation of beneficial microorganisms called lactobacilli. ... improve feed efficiency in animals and combat malnutrition in ... residents of the human gastrointestinal and urogenital tracts, where ...
... 3, 2013 /PRNewswire-iReach/ -- With the myriad of exercise and ... results fast, it can be difficult for people to discern ... Belt Critic aims to provide detailed information on one abdominal ... customer base of more than two million people – the ...
... research results of the VTT Technical Research Centre of Finland, ... biofuels for the price of less than one euro per ... of more than half the energy of wood raw materials ... construction of a commercial-scale production plant in Europe. VTT ...
Cached Biology News:Newly developed medium may be useful for human health, biofuel production, more 2Detailed Flex Belt Review and Announcement of New Discount Coupon at Flex Belt Critic Site 2Gasification method turns forest residues to biofuel with less than a euro per litre 2
...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
...
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Biology Products: